Bioretec Ltd. Achieves CE Mark Approval
Bioretec Ltd., a leader in absorbable orthopedic implants, has exciting news. The company has received CE mark approval, which allows for the marketing of its RemeOs™ Trauma Screw product portfolio across Europe and other territories recognizing this certification. This vital achievement covers all product designs, including both cannulated and non-cannulated screws, with diameters ranging from 2.0mm to 4.0mm and lengths from 8mm to 50mm.
Wide Range of Indications for Trauma Screws
The newly approved screws are indicated for the fixation of fractures and malalignments in the upper and lower limbs of both adults and children, excluding the hand and forefoot. This wide range of applications makes the RemeOs™ Trauma Screws an essential component in orthopedic surgery, improving outcomes for patients requiring surgical intervention.
Immediate Market Access Across Europe
Alan Donze, the CEO of Bioretec, expressed optimism about the approval stating, "We are thrilled that the EU market approval includes all designs and numerous indications. This enables us to offer RemeOs™ Trauma Screws promptly to patients throughout Europe." Furthermore, this approval opens doors for Bioretec to expand into non-European markets that recognize the CE mark, thereby allowing them to gather substantial clinical evidence from real-world use.
Innovation in Biodegradable Materials
Bioretec is at the forefront of developing biodegradable orthopedic implants. Their RemeOs™ line is based on innovative magnesium alloy and hybrid composite materials that prioritize patient outcomes. These implants dissolve and are gradually replaced by bone, eliminating the need for removal surgeries while enhancing the healing process for fractures.
Growth Potential in the Orthopedic Market
With the first market authorization for the RemeOs™ products obtained in the U.S. and the CE mark secured in Europe, Bioretec is strategically positioning itself to tap into the ever-expanding global orthopedic trauma market, valued over USD 9 billion. Their commitment to enhancing surgical solutions and customer value presents a significant opportunity to revolutionize treatment methods for bone fractures.
Company Overview and Vision
Bioretec is a Finnish medical device firm dedicated to pioneering biodegradable implants that foster better healing outcomes. They have established unique capabilities concerning the biological interface of active implants, enabling superior bone growth and faster recovery times post-surgery. The products developed by Bioretec are currently utilized in around 40 countries worldwide.
Contact Information
For further inquiries regarding Bioretec Ltd., please reach out to:
Alan Donze, CEO: +1 619 977 5285
Johanna Salko, CFO: +358 40 754 8172
Frequently Asked Questions
What is the significance of CE mark approval for Bioretec?
The CE mark approval signifies that Bioretec's RemeOs™ products meet essential health, safety, and environmental protection requirements for sale in the European market.
What applications are covered under the RemeOs™ Trauma Screws?
The RemeOs™ Trauma Screws are approved for fracture and malalignment fixations in adult and pediatric patients, excluding the hand and forefoot.
How does Bioretec's technology differ from traditional implants?
Bioretec's implants are biodegradable, meaning they are absorbed by the body and replaced by bone, which reduces the need for surgical removal and promotes healing.
In how many countries is Bioretec's technology currently available?
The products from Bioretec are currently used in approximately 40 countries around the globe.
What are Bioretec's future plans in the orthopedic market?
Bioretec aims to expand its presence in the global orthopedic trauma and spine market, focusing on innovative solutions that enhance patient care and outcomes.
